Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
Become a Member | Sign in
Home>News>This Article

A Phenomenal Legacy for London 2012

Published: Wednesday, August 01, 2012
Last Updated: Wednesday, August 01, 2012
Bookmark and Share
The Phenome Centre will use the cutting edge facilities developed for London 2012 to help develop better and more targeted treatment for patients.

The London 2012 anti-doping facilities will be developed after the Olympic and Paralympic Games into a world-class resource that could help revolutionise healthcare. The MRC-NIHR Phenome Centre will use the cutting edge facilities developed for London 2012 to help develop better and more targeted treatment for patients.
The MRC-NIHR Phenome Centre, the first of its kind in the world, will enable researchers to explore the characteristics of disease in order to develop new drugs and treatments for patients.
A phenome describes a person’s chemistry – all the molecules in their blood, urine or tissues – that are the result of their genetics and their lifestyle. This mixture of molecules is changing all the time and is influenced by factors such as diet, environment and even stress levels. It is linked to how a person responds to disease or to treatments such as drugs.
Researchers at the Centre will investigate the phenome patterns of patients and volunteers by analysing samples – usually blood or urine – very rapidly and on an unprecedented scale. This will help them to discover new ‘biomarkers’ to explain why one individual or population may be more susceptible to a disease than another. This knowledge will aid scientists in finding new, safer and more targeted treatments. Phenome analysis has already been used to ‘tailor’ cancer treatment to suit individual patients by, for example, minimising the toxicity and maximising the efficiency of drug treatments for colon cancer.
The new Centre will be funded over five years by an investment of £5 million each from the Medical Research Council (MRC) and the Department of Health’s National Institute for Health Research (NIHR) and will build on and develop the state-of-the-art equipment and expertise of the London 2012 anti-doping facilities provided by GlaxoSmithKline (GSK) and operated by King’s College London.
The MRC-NIHR Phenome Centre will enable the UK to make its world-class phenotyping technology and expertise available to both researchers and the life sciences industry to accelerate the translation of medical discoveries into better healthcare. The new Centre will be led by a collaboration of academic partners, led by Imperial College London, and the suppliers of nuclear magnetic resonance and mass spectrometry equipment (Bruker and Waters Corporation).
Professor Sir John Savill, Chief Executive of the MRC, said:

“The UK has an extremely strong life sciences capability and world-class expertise in this area of research. The GSK drug-testing facility at Harlow has taken one of the major challenges associated with this type of research – achieving high-throughput alongside forensic quality control – to a new level, unprecedented anywhere in the world. Rather than losing this investment once the Games are over the collaboration – involving the MRC, NIHR, UK universities, the NHS and NIHR Biomedical Research Centres, and industry leaders in the field – will provide a unique resource that will ultimately result in benefits for patients. This is a phenomenal legacy from the Games.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Flowing Electrons Help Ocean Microbes Gulp Methane
Recent work at Caltech has shown that microbes work together to consume large amounts of methane released from vents on the ocean floor by using electrons to share energy over long distances.
Thousands of Protein Interactions Identified
Thanks to the work by Utrecht University researcher Fan Liu and her colleagues, it is now possible to map the interactions between proteins in human cells.
Newly Identified Biochemical Pathway Could Be Target for Insulin Control
Researchers at Duke Medicine and the University of Alberta are reporting the identification of a new biochemical pathway to control insulin secretion from islet beta cells in the pancreas, establishing a potential target for insulin control.
Dirty,Crusty Meals Fit for (Long-Dormant) Microbes
Researchers apply the latest analytical techniques to further our understanding of desert biocrusts.
CSI -- On The Metabolite's Trail
Bioinformaticians at the University of Jena make the most efficient search engine for molecular structures available online.
First Complete Structural Study Of A Pegylated Protein
Significant data obtained at NUI Galway reports first crystal structure of a protein modified with a single PEG chain.
Potential Ovarian Cancer Biomarker Isolated
Researchers from North Carolina State University utilized a highly sensitive mass spectrometry analysis to identify and measure difficult-to-detect N-glycan biomarkers associated with ovarian cancers in stages I – IV.
Waters’ Centers of Innovation Program Honors Ohio State University Laboratory
Wysocki-led facility recognized for proteomics, disease research and mass spectrometry excellence.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos